Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well nelfinavir mesylate works in treating patients
with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
AIDS and Cancer Specimen Resource Montefiore Medical Center National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation University of Arkansas University of California, Los Angeles